Literature DB >> 34855092

Expression and Content of Protein LC3B in Gastric Cancer Tissue, Relationship with Expression of mTOR, AMPK in Gastric Cancer Tissue and HER2 and PD-L1 Status of the Tumor.

L V Spirina1, A V Avgustinovich2, S G Afanas'ev2, M Yu Volkov2, I V Kondakova2.   

Abstract

Analysis of HER2 status of the tumor and expression of mTOR, AMPK showed a decrease in mTOR mRNA level in HER2+ tumors in comparison with HER- status. The appearance of PD-L1+ transformed cells in the tumor was associated with increased expression of the LC3B gene and elevated content of the corresponding protein measured after treatment.
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  HER2 tumor status; LC3B; PD-L1 tumor status; gastric cancer

Mesh：

Substances：

Year:  2021        PMID： 34855092     DOI： 10.1007/s10517-021-05376-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  13 in total

1.  LC3A, LC3B and Beclin-1 Expression in Gastric Cancer.

Authors:  Alexandra Giatromanolaki; Michael I Koukourakis; Ioannis Georgiou; Maria Kouroupi; Efthimios Sivridis
Journal:  Anticancer Res       Date:  2018-12       Impact factor: 2.480

2.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.

Authors:  Oscar Tapia; Ismael Riquelme; Pamela Leal; Alejandra Sandoval; Susana Aedo; Helga Weber; Pablo Letelier; Enrique Bellolio; Miguel Villaseca; Patricia Garcia; Juan Carlos Roa
Journal:  Virchows Arch       Date:  2014-05-21       Impact factor: 4.064

3.  Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy.

Authors:  Liudmila V Spirina; Alexandra V Avgustinovich; Sergey G Afanas'ev; Olga V Cheremisina; Maxim Yu Volkov; Evgeny L Choynzonov; Alexey K Gorbunov; Evgeny A Usynin
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

4.  Prognostic Significance of LC3B and p62/SQSTM1 Expression in Gastric Adenocarcinoma.

Authors:  Ju Seok Kim; Go Eun Bae; Kyung-Hee Kim; Sang-Il Lee; Chaeuk Chung; Dahye Lee; Tae Hee Lee; In Sun Kwon; Min-Kyung Yeo
Journal:  Anticancer Res       Date:  2019-12       Impact factor: 2.480

Review 5.  Autophagy and its role in gastric cancer.

Authors:  Yijing Cao; Yichen Luo; Juan Zou; Jun Ouyang; Zhihong Cai; Xi Zeng; Hui Ling; Tiebing Zeng
Journal:  Clin Chim Acta       Date:  2018-11-22       Impact factor: 3.786

Review 6.  Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks.

Authors:  Sebastian Alers; Antje S Löffler; Sebastian Wesselborg; Björn Stork
Journal:  Mol Cell Biol       Date:  2011-10-24       Impact factor: 4.272

7.  The role of autophagy in HER2-targeted therapy.

Authors:  Félice A Janser; Mario P Tschan; Rupert Langer
Journal:  Swiss Med Wkly       Date:  2019-10-27       Impact factor: 2.193

8.  TIPRL, a Novel Tumor Suppressor, Suppresses Cell Migration, and Invasion Through Regulating AMPK/mTOR Signaling Pathway in Gastric Cancer.

Authors:  Meng Luan; Shan-Shan Shi; Duan-Bo Shi; Hai-Ting Liu; Ran-Ran Ma; Xiao-Qun Xu; Yu-Jing Sun; Peng Gao
Journal:  Front Oncol       Date:  2020-07-03       Impact factor: 6.244

9.  HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.

Authors:  Natasha Tracey; Helen Creedon; Alain J Kemp; Jayne Culley; Morwenna Muir; Teresa Klinowska; Valerie G Brunton
Journal:  Breast Cancer Res Treat       Date:  2019-11-08       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.